Pullarkat, Vinod
Feng Q, Besevic J, Conroy M, Omiyale W, Woodward M, Lacey B et al (2024) Waist-to-height ratio and body fat percentage as risk factors for ischemic cardiovascular disease: a prospective cohort study from uk biobank
Although guidelines suggest cautious use in compensated cirrhosis and avoidance in decompensated liver disease, a large retrospective cohort study found no significant drug-induced liver injury from naltrexone and no attributed decompensations, supporting its use in both compensated and decompensated cirrhosis with close monitoring [120,121]
How is it different from approved GLP-1 medications
Transcript: Most often, [members of] the oncology team are not the ones initiating a GLP-1 agent because the indication is obesity and diabetes, so these agents are being initiated by their primary care doctors, endocrinologists, etc